Why the study?
Do selective COX-2 inhibitors increase the risk of cardiovascular thrombotic events compared to nonnaproxen NSAIDs in a high-risk Medicaid population?
Population
6,250 noninstitutionalized Maryland Medicaid enrollees who received at least a 60-day supply of a COX-2…
Comparison
Selective cyclooxygenase-2 inhibitors vs Nonspecific nonsteroidal anti-inflammatory…
Design
Cohort
Authors
Loading...
COX-2 inhibitor use was not associated with excess thrombotic risk versus nonnaproxen NSAIDs; leaves open need for randomized confirmation.
Do selective COX-2 inhibitors increase the risk of cardiovascular thrombotic events compared to nonnaproxen NSAIDs in a high-risk Medicaid population?
In a high-risk Medicaid population, the use of COX-2 inhibitors did not significantly increase the risk of cardiovascular thrombotic events compared to nonnaproxen NSAIDs.
Fadia T. Shaya (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: